{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:06Z","timestamp":1786119486047,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/mph.0b013e3181d419d6","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T02:41:53Z","timestamp":1269312113000},"page":"267-273","source":"Crossref","is-referenced-by-count":4,"title":["Iron Chelation Therapy in Upper Egyptian Transfusion-dependent Pediatric Homozygous \u03b2-Thalassemia Major"],"prefix":"10.1097","volume":"32","author":[{"given":"Enas A.","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek H.","family":"EL-Metwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal M.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210227","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00774-003-0449-z","article-title":"Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs","volume":"22","author":"Di Stefano","year":"2004","journal-title":"J Bone Miner Metab"},{"key":"R2-3-20210227","first-page":"107","article-title":"Hormonal dysregulation and bones in thalassemia-an overview","volume":"6","author":"Skordis","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"key":"R3-3-20210227","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2141.2004.05143.x","article-title":"New insights into the pathophysiology and management of osteoporosis in patients with \u03b2-thalassaemia","volume":"127","author":"Voskaridou","year":"2004","journal-title":"Br J Haematol"},{"key":"R4-3-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1359-6101(00)00030-7","article-title":"Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands","volume":"12","author":"Horowitz","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"R5-3-20210227","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"39","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"R6-3-20210227","first-page":"7","article-title":"Effect of L-carnitine on growth of Egyptian children with thalassemia major","volume":"69","author":"El Beshlawy","year":"2001","journal-title":"Med J Cairo Univ"},{"key":"R7-3-20210227","first-page":"115","article-title":"Carnitine Biosynthesis, Metabolism and Functions","author":"Borum","year":"1980"},{"key":"R8-3-20210227","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1042\/bj2480129","article-title":"Fatty acid oxidation in bone tissue and bone cells in culture","volume":"248","author":"Adamek","year":"1987","journal-title":"Biochem J"},{"key":"R9-3-20210227","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00223-004-0147-4","article-title":"L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro","volume":"76","author":"Colucci","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"R10-3-20210227","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2165\/00003495-200767150-00007","article-title":"Deferasirox","volume":"67","author":"Yang","year":"2007","journal-title":"Drugs"},{"key":"R11-3-20210227","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/oxfordjournals.jbchem.a133380","article-title":"A new colorimetric method for the determination of free fatty acids with ccyl-CoA synthetase and acyl-CoA oxidase","volume":"89","author":"Hosaka","year":"1981","journal-title":"J Biochem"},{"key":"R12-3-20210227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jaoac\/78.1.69","article-title":"Enzymatic determination of free carnitine in milk and infant formulas","volume":"78","author":"Indyk","year":"1995","journal-title":"J AOAC Int"},{"key":"R13-3-20210227","first-page":"810","article-title":"Determination of free and total carnitine with a random-access chemistry analyzer","volume":"44","author":"Wan","year":"1998","journal-title":"Clin Chem"},{"key":"R14-3-20210227","first-page":"902","article-title":"Bone mineral metabolism in adults with \u03b2-thalassemia major and intermedia","volume":"111","author":"Dresner Pollack","year":"2000","journal-title":"Br J Haematol"},{"key":"R15-3-20210227","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-3476(99)70020-X","article-title":"Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia","volume":"135","author":"Leonard","year":"1999","journal-title":"J Pediatr"},{"key":"R16-3-20210227","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2005.00358.x","article-title":"Biochemical markers of bone turnover and bone mineral density in patients with \u03b2-thalassemia major","volume":"59","author":"Eren","year":"2005","journal-title":"Int J Clin Pract"},{"key":"R17-3-20210227","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2141.1998.01107.x","article-title":"Bone disease in \u03b2-thalassemia major","volume":"103","author":"Wonke","year":"1998","journal-title":"Br J Hematol"},{"key":"R18-3-20210227","first-page":"1003","article-title":"Identification of an OSF-2 binding site in the murine RANKL\/OPGL gene promoter: a potential link between osteoblastogenesis and osteoclastogenesis","volume":"23","author":"O'Brien","year":"1998","journal-title":"Bone"},{"key":"R19-3-20210227","doi-asserted-by":"crossref","first-page":"c1","DOI":"10.1159\/000081787","article-title":"New prospects for the management of renal bone disease","volume":"99","author":"Steddon","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"R20-3-20210227","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00774-006-0728-6","article-title":"Circulating osteoprotegerin and receptor activator of NF-\u03baB ligand system in patients with \u03b2-thalassemia major","volume":"25","author":"Angelopoulos","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"R21-3-20210227","first-page":"1193","article-title":"Zoledronic acid for the treatment of osteoporosis in patients with \u03b2-thalassemia: results from a single-center, randomized, placebo-controlled trial","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"key":"R22-3-20210227","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.040113","article-title":"Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle","volume":"19","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R23-3-20210227","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.bone.2007.02.020","article-title":"The \u201clively\u201d cytokines network in \u03b2-thalassemia major-related osteoporosis","volume":"40","author":"Morabito","year":"2007","journal-title":"Bone"},{"key":"R24-3-20210227","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00277-006-0180-7","article-title":"Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with \u03b2-thalassaemia","volume":"86","author":"Perifanis","year":"2007","journal-title":"Ann Hematol"},{"key":"R25-3-20210227","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.2003.04657.x","article-title":"Pamidronate is an effective treatment for osteoporosis in patients with \u03b2-thalassaemia","volume":"123","author":"Voskaridou","year":"2003","journal-title":"Br J Haematol"},{"key":"R26-3-20210227","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0609.2004.00395.x","article-title":"Osteoprotegerin to soluble receptor activator of nuclear factor kappa-\u03b2 ligand ratio is reduced in patients with thalassemia-related osteoporosis who receive vitamin D3","volume":"74","author":"Voskaridou","year":"2005","journal-title":"Eur J Haematol"},{"key":"R27-3-20210227","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","article-title":"Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption","volume":"7","author":"Kostenuik","year":"2001","journal-title":"Curr Pharm Des"},{"key":"R28-3-20210227","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R29-3-20210227","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"R30-3-20210227","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10834","article-title":"Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates","volume":"48","author":"Alvarez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R31-3-20210227","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00003495-200767050-00004","article-title":"Optimal management strategies for chronic iron overload","volume":"67","author":"Barton","year":"2007","journal-title":"Drugs"},{"key":"R32-3-20210227","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00431-004-1590-y","article-title":"Serum carnitine levels in patients with homozygous \u03b2-thalassemia: a possible new role for carnitine?","volume":"164","author":"Tsagris","year":"2005","journal-title":"Eur J Pediatr"},{"key":"R33-3-20210227","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00223-008-9109-6","article-title":"L-carnitine fumarate and isovaleryl-L-carnitine fumarate accelerate the recovery of bone volume\/total volume ratio after experimentally induced osteoporosis in pregnant mice","volume":"82","author":"Patano","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"R34-3-20210227","first-page":"975","article-title":"High incidence of osteoporosis in thalassemia major","volume":"11","author":"Jensen","year":"1998","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R35-3-20210227","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1196\/annals.1345.063","article-title":"Low bone mineral density in adolescents with beta-thalassemia","volume":"1054","author":"Vogiatzi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R36-3-20210227","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1196\/annals.1345.021","article-title":"Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of \u03b2-thalassemia patients with transfusional iron overload","volume":"1054","author":"Galanello","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R37-3-20210227","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/08880010701533702","article-title":"Bone mineral density in Iranian adolescents and young adults with \u03b2-thalassemia major","volume":"24","author":"Shamshirsaz","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"key":"R38-3-20210227","first-page":"116","article-title":"Gender differences in the prevalence and severity of bone disease in thalassemia","volume":"6","author":"Kyriakou","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"key":"R39-3-20210227","doi-asserted-by":"crossref","first-page":"334","DOI":"10.14310\/horm.2002.1111030","article-title":"Normal lumbar bone mineral density in optimally treated children and young adolescents with \u03b2-thalassemia major","volume":"6","author":"Christoforidis","year":"2007","journal-title":"Hormones"},{"key":"R40-3-20210227","first-page":"461","article-title":"Osteoporosis in \u03b2-thalassemia major patients: analysis of the genetic background","volume":"111","author":"Perotta","year":"2000","journal-title":"Br J Haematol"},{"key":"R41-3-20210227","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-3-20210227","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1359\/jbmr.1999.14.4.518","article-title":"Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis","volume":"14","author":"Yano","year":"1999","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e3181d419d6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:16:28Z","timestamp":1786040188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201005000-00003"}},"subtitle":["Impact on Serum L-Carnitine\/Free Fatty Acids, Osteoprotegerin\/The Soluble Receptor Activator of Nuclear Factor-\u03ba\u03b2 Ligand Systems, and Bone Mineral Density"],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3181d419d6","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}